Merck raises revenue outlook, cuts profit guidance on Terns Pharmaceuticals deal charge
RAHWAY, N.J., August 6. Merck lifted its full-year revenue outlook after new drug sales grew, then cut its profit guidance in the same release to reflect a charge from its acquisition of biotech company Terns Pharmaceuticals. The two lines move in opposite directions, and the profit cut traces back to one cause: the Terns deal.
Key takeaways
- Merck raised its full-year revenue outlook on the strength of growing new-drug sales.
- Merck simultaneously cut its full-year profit guidance in the same release.
- The profit guidance cut is directly attributed to a charge from Merck's acquisition of biotech company Terns Pharmaceuticals.
- The revenue and profit guidance lines moved in opposite directions, with the Terns deal charge cited as the sole cause of the profit reduction.
RAHWAY, N.J., August 6. Merck lifted its full-year revenue outlook after new drug sales grew, then cut its profit guidance in the same release to reflect a charge from its acquisition of biotech company Terns Pharmaceuticals. The two lines move in opposite directions, and the profit cut traces back to one cause: the Terns deal.
Revenue driven by new drug sales
Merck raised its revenue forecast on the strength of growing new-drug sales, according to the company's release. The better commercial performance in that segment gave management room to revise the outlook higher.
Growing sales in newer products is the kind of result Merck would headline. The profit line tells a different story.
Profit guidance cut tied to Terns acquisition
The company simultaneously lowered its profit guidance, citing charges connected to the acquisition of Terns Pharmaceuticals. Merck disclosed the charge as the direct cause of the profit guidance reduction, the company said.
Terns Pharmaceuticals is a biotech company. The acquisition generated deal-related charges that Merck folded into its revised earnings outlook.
Acquisition charges of this kind are often framed as one-time items. They still reduce reported profit, and they set a lower base against which future quarters will be compared.
The split guidance
A revenue beat paired with an earnings cut is the type of result that splits investor reaction. Profit guidance falling signals a cost that landed in this reporting period, whatever the commercial momentum behind the revenue line.
The charge from the Terns Pharmaceuticals acquisition is, by Merck's own accounting, the reason profit guidance moved lower while revenue guidance moved higher.